Use of active detoxification methods with delayed elimination of methotrexate after high-dose infusion in a child with osteogenic sarcoma: clinical observation

This article represents clinical case presentation of delayed elimination of methotrexate (MTX) after high dose infusion at a patient of 12 years old with morphologically approved osteosarcoma of proximal metadiaphisis of left tibia. This boy received specific drug therapy in clinic of N.N. Petrov National Research Center of Oncology by EURAMOS program. Common time of excretion was increased to 144 hours and accompanied by kidney, liver and hematological toxicity of 2–4 gr. Abovementioned condition was eliminated by substitutive, infusion and symptomatic therapy. Patient was discharged in satisfactory condition on 12 day after MTX infusion. As a rule, prolonged excretion of MTX is connected with dysfunction of enzymes participating in intracellular metabolism of cytostatic. Data on pharmacokinetics and pharmacodynamics of drug which to a large extent allows to explain disturbance of excretion of MTX from blood serum discussed. Genes with mutations influencing on enzymes function and MTX metabolism, which are decreasing elimination of abovementioned drug and increasing toxicity are already known. Article represents method of application of high doses of antagonist of leucovorin antifolates (calcium folinate) and intensification of efferent therapy with plasma exchange procedures. Detailed algorithm of treatment of different complications associated with delayed excretion of MTX from blood serum proposed.

children, , methotrexate, delayed elimination, leucovorin, plasma exchange, osteogenic sarcoma

1. Crews K.R., Liu T., Rodriguez-Galindo C. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer 2004;100(8):1724–33. doi: 10.1002/ cncr.20152.

2. Ferreri A.J.M., Guerra E., Regazzi M. et al. Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. Br J Cancer 2004;90(2):353–8. doi: 10.1038/ sj.bjc.6601472.

3. Joerger M., Huitema A.D., Krähenbühl S. et al. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010;102(4):673–7. doi: 10.1038/sj. bjc.6605559.

4. Невожай Д.В., Будзынская Р., Каньская У. и др. Современные представления о механизме противоопухолевого действия метотрексата и устойчивости к нему. Тихоокеанский медицинский журнал 2006;4:12–6. [Nevozhaj D.V., Budzynskaya R., Kan’skaya U. et al. Modern ideas about the mechanism of antineoplastic action of methotrexate and resistance to it. Tihookeanskiy medicinskiy zhurnal = Pacific Medical Journal 2006;4:12–6. (In Russ.)].

5. Lee K.M., Lee H.W., Kim S.Y. et al. Two pediatric osteosarcoma cases with delayed methotrexate excretion: its clinical course and management. Cancer Res Treat 2011;43(1):67–70. doi: 10.4143/ crt.2011.43.1.67.

6. Al-Turkmani M.R., Law T., Narla A., Kellogg M.D. Difficulty measuring methotrexate in a patient with high-dose methotrexate-induced nephrotoxicity. Clin Chem 2010;56(12):1792–4. doi: 10.1373/ clinchem.2010.144824.

7. Ikeda H., Kihira K., Kuwata N. et al. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy. Hiroshima J Med Sci 1996;45(2):57–62. PMID: 8810132.

8. Widemann B.C., Balis F.M., Kim A. et al. Glucarpidase, leucovorin, and thymidine for high-dose methotrexate-induced renal dysfunction: clinical and pharmacologic factors affecting outcome. J Clin Oncol 2010;28(25):3979–86. doi: 10.1200/ JCO.2009.25.4540.

9. Кулева С.А. Замедленная элиминация метотрексата после высокодозной инфузии. Вопросы онкологии 2013;1: 126–31. [Kuleva S.A. Delayed elimination of methotrexate after high-dose infusion. Voprosy onkologii = Problems in Oncology 2013;1:126–31. (In Russ.)].

10. Кулева С.А., Карелов А.Е. Способ лечения замедленной элиминации метотрексата после его высокодозной инфузии при опухолях головного мозга. Патент на изобретение 2516924, опубликовано 20.05.2014. Бюллетень № 14. http://www.freepatent.ru/images/img_ patents/2/2516/2516924/patent-2516924. pdf. [Kuleva S.A., Karelov A.E. The method of treatment of delayed elimination of methotrexate after its high-dose infusion in brain tumors. Patent for invention 2516924, published May 20, 2014. Bulletin No. 14. (In Russ.)].

11. Bremnes R.M., Slørdal L., Wist E., Aarbakke J. Formation and elimination of 7-hydroxymethotrexate in the rat in vivo after methotrexate administration. Cancer Res 1989;49(9):2460–4. PMID: 2706634.

12. Widemann B.C., Sung E., Anderson L. et al. Pharmacokinetics and metabolism of the methotrexate metabolite 2, 4-diamino-N(10)-methylpteroic acid. J Pharmacol Exp Ther 2000;294(3):894–901. PMID: 10945838.

13. Joerger M., Huitema A.D., van den Bongard H.J. et al. Determitants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br J Clin Pharmacol 2006;62(1):71–80. doi: 10.1111/j.1365-2125.2005.02513.x.

14. Пименова М.А., Соколов А.Н., Бирюкова Л.С. и др. Экстремально высокая концентрация метотрексата в сыворотке крови, сопровождавшаяся острой почечной недостаточностью у больного острым лимфобластным лейкозом после высокодозной консолидации. Терапевтический архив 2011;83(7):58–61. [Pimenova M.A., Sokolov A.N., Biryukova L.S. et al. Extremely high concentration of mexotrexate in blood serum leading to development of acute renal failure in a patient with acute lymphoblastic leukemia after high-dose consolidation. Terapevticheskiy arkhiv = Therapeutic Archive 2011;83(7):58–61. (In Russ.)].

15. Vlaming M.L., van Esch A., Pala Z. et al. Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Mol Cancer Ther 2009;8(12):3350–9. doi: 10.1158/1535-7163.MCT-09-0668.

16. Mashhadi M.A., Kaykhaei M.A., Sanadgol H. Low prevalence of high-dose methotrexate nephropathy in patients with malignancy. Iran J Kidney Dis 2012;6(2):105–9. PMID: 22388607.

17. Widemann B.C., Adamson P.C. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006;11(6):694–703. doi: 10.1634/theoncologist.11-6-694.

18. Treon S.P., Chabner B.A. Concepts in use of high-dose methotrexate therapy. Clin Chem 1996;42(8 Pt 2):1322–9. PMID: 8697606.

19. Sowers R., Wenzel B.D., Richardson C. et al. Impairment of methotrexate transport is common in osteosarcoma tumor samples. Sarcoma 2011;2011:834170. doi: 10.1155/2011/834170